ALXN Alexion Pharmaceuticals Inc.

123.04
+2.22  (+2%)
Previous Close 120.82
Open 120.72
Price To Book 2.84
Market Cap 27,590,146,811
Shares 224,237,214
Volume 928,973
Short Ratio
Av. Daily Volume 1,448,582

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b/3 trial to be initiated early 2020.
CAEL‐101
AL amyloidosis
FDA Approval announced June 27, 2019.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
PDUFA data under priority review October 19, 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 enrolment to be completed early 2020.
ALXN1840 (WTX101)
Wilson disease
Phase 3 trial initiated 1Q 2019.
ULTOMIRIS (ravulizumab-cwvz)
Generalized myasthenia gravis (gMG)
Phase 1b/2a trial to be completed in 2019.
ALXN1830
Warm autoimmune hemolytic anemia (WAIHA)
Phase 3 PK data due early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)

Latest News

  1. How Much Are Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Insiders Taking Off The Table?
  2. 3 Top Biotech Stocks to Buy for the 2nd Half of 2019
  3. Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019
  4. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  5. Health stocks under pressure in wake of Trump plan to issue executive order on drug pricing
  6. Alexion's Ultomiris Receives EU Approval for PNH in Adults
  7. ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
  8. How to Invest in Biotech Stocks
  9. 3 Top Biotech Stocks to Add to Your Watchlist
  10. Alexion Receives FDA Approval for Label Expansion of Soliris
  11. ADDING MULTIMEDIA Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive
  12. Best Stocks to Buy Before July
  13. Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
  14. 8 Stocks May Jump on Takeovers as Market Nears Peak
  15. Alexion's sBLA for Ultomiris Gets Priority Review From FDA
  16. 3 Big Biotechs Hold Growth Potential in Second Half of 2019
  17. The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
  18. U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)
  19. Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
  20. Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data